What you must know:

– Dexcom, the worldwide chief in steady glucose monitoring (CGM), has achieved one other groundbreaking milestone by launching the primary generative AI (GenAI) platform in glucose biosensor know-how, Stelo.

– The Stelo platform analyzes particular person well being information patterns to offer personalised insights and proposals for bettering metabolic well being.

AI-powered private steering

The Dexcom GenAI platform makes use of Google Cloud's Vertex AI and Gemini fashions to investigate consumer information and generate personalised insights round diet, train and sleep. This know-how enhances Dexcom's present Weekly Insights characteristic and supplies customers with extra personalised steering and assist as they handle their well being.

Stelo: the primary GenAI-compatible CGM

Stelo, Dexcom's over-the-counter glucose biosensor, is the primary product to combine this GenAI know-how. Customers now obtain personalised ideas, suggestions and training throughout the Stelo app, permitting them to make knowledgeable selections about their well being.

Key advantages of Dexcom's GenAI platform

• Personalised insights: Offers customers with tailor-made steering primarily based on their particular person well being information patterns.
• Improved Metabolic Well being: Helps customers perceive the influence of way of life decisions on their glucose ranges and make knowledgeable selections to enhance their metabolic well being.
• Improved consumer expertise: Delivers personalised content material and proposals throughout the Stelo app, making it simpler for customers to handle their well being.
• Innovation in glucose biosensors: Positions Dexcom as a frontrunner within the integration of AI with CGM know-how.

Growth plans for Stelo

Dexcom plans to develop its GenAI platform throughout its product portfolio and provide extra personalised and insightful well being administration instruments to hundreds of thousands of customers worldwide. This know-how has the potential to revolutionize diabetes care and enhance the lives of individuals with metabolic ailments.

“The launch of our GenAI platform reinforces our long-standing fame as a frontrunner in glucose biosensors and opens the door for future enhancements to our product portfolio,” stated Jake Leach, government vice chairman and chief working officer at Dexcom. “Innovation is on the core of what we do. We sit up for introducing further GenAI-powered options within the coming yr to assist customers contextualize their well being data and make proactive, knowledgeable way of life selections.”